Most Recent Articles by Larry Dobrow
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of power may well have shifted—but not to the degree that many observers had predicted
Anne Whitaker, President and CEO, Synta Pharmaceuticals
It's not as though pharma marketers didn't see mobile coming. For the past half decade, they've discussed its potential to transform behaviors and relationships within the healthcare ecosystem. Yet now that mobile has arrived, they find themselves torn between caution and exuberance. Larry Dobrow explains
Thomas Sack, President and CEO, MRIGlobal
More Articles by Larry Dobrow
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.